Earendil Labs signed a global license and development pact with WuXi XDC worth up to $885 million to use WuXi’s payload‑linker technology and CRDMO capabilities for antibody‑drug conjugate (ADC) programs. Earendil will lead product development, global regulatory submissions and commercialization while WuXi handles CMC and manufacturing support. Earendil also presented preclinical or early clinical data on HXN‑1031, a dual‑targeting T‑cell engager for B‑cell malignancies, reinforcing its pipeline push in engineered biologics. The alliance underscores continued investment in next‑generation ADC chemistry and integrated outsourcing models that combine discovery, payload/linker expertise and scalable manufacturing.